Ingibitory GMG-KoA-reduktazy pri vtorichnoy profilaktike ateroskleroza: 30 let spustya


Cite item

Full Text

Abstract

ГМГ-КоА-редуктазы (статины) были открыты японскими учеными А.Эндо и М.Курода в начале 70-х годов. С начала 80-х годов начались широкомасштабные клинические исследования статинов в липидных клиниках США. В статье обсуждаются вопросы эффективности, безопасности статинов спустя 30 лет после их открытия и начала применения в клинической практике. Применение статинов в РФ имеет очень большие перспективы. Более активное назначение ингибиторов ГМГ-КоА-редуктазы, усиление приверженности к терапии, ориентир на данные доказательной медицины – вполне выполнимые задачи для каждого российского врача.

About the authors

A. V Susekov

Институт клинической кардиологии им А.Л.Мясникова РКНПК МЗ и СР РФ

References

  1. Pollac O.J. Circulation 1953; 7: 702–6.
  2. Endo A. J Lipid Res 1992; 33: 1569–82.
  3. Endo A, Kuroda M, Tsujita Y. J Antibiot (Jpn) 1976; 29: 1346–8.
  4. Brown A.G, Smale T.C, King R et al. J Chem Soc Perkin I 1976; 1165–70.
  5. Yamomoto A, Endo A, Kitano Y et al. Jpn J Med 1978; 17: 230–9.
  6. Сусеков А.В. Тер. арх. 2001; 4: 76–80.
  7. Roberts W. Am J Cardiol 1997; 80: 106–7.
  8. Giveira F. Atherosclerosis 2004; 173: 55–68.
  9. Stein E.A, Lane M, Laskarzewski P. Am J Cardiol 1998 Feb 26; 81 (4A): 66B–9B.
  10. Eckardstein A, Assmann G. Cur Opin Lipidol 2000; 11: 627–37.
  11. Crouse J.R, Frohlich J, Ose L, Mercuri M, Tobert J.A. Am J Cardiol 1999; 83 (10): 1476–7.
  12. Wierzbicki A.S, Lumb P.J, Chick G, Crook M.A. J Clin Pract 1999; 53 (8): 609–11.
  13. Schaefer J.R, Schweer H, Ikewaki K et al. Atherosclerosis 1999; 144: 177–84.
  14. Celermajer D.S, Sorensen K.E, Gooch V.M et al. Lancet 1992; 340: 1111–5.
  15. O’Driscoll G, Green D, Taylor R.R. Circulation 1997; 95 (5): 1126–31.
  16. Балахонова Т.В., Погорелова О.А., Сусеков А.В. и др. Кардиология. 2002; 1: 15–21.
  17. Балахонова Т.В., Погорелова О.А., Лагута П.С. и др. В кн.: Съезд Ассоциации специалистов ультразвуковой диагностики в медицине. 3-й. Тезисы докладов. М., 1999; 34.
  18. Corsini A. J Cardiovasc Pharmacol Ther 2000; 5 (3): 161–75.
  19. Hussein O, Schlezinger S, Rosenblat M. Atherosclerosis 1997; 128: 11–8.
  20. Aviram M, Hussein O, Rosenblat M et al. J Cardiovasc Pharmacology 1998; 31: 39–45.
  21. Guethlin M, Kasel A.M, Coppenrath K et al. Circulation 1999; 9: 475–81.
  22. Herd J.A, Ballantyne C.M, Farmer J.A et al. Am J Cardiol 1997; 80: 278–86.
  23. Ross R. N Engl J Med 1999; 340: 115–26.
  24. Albert M.A, Danielson E, Rifai N, Ridker P.M. JAMA 2001; 286: 64–70.
  25. Karas R.H. J Thromb Thrombolysis 1997; 4: 167–75.
  26. Ridker P.M. Circulation 2003; 107: 363–9.
  27. Ballantyne C.M, Houri J, Notarbartolo A et al. Circulation 2003; 107: 2409–15.
  28. van de Ree M.A, Huisman M.V, Princen H.M et al. Atherosclerosis 2003; 166: 129–35.
  29. Dangas G, Badimon J.J, Smith D.A et al. J Am Coll Cardiol 1999; 33: 1294–304.
  30. Chan D.C, Watts G.F, Barrett P.H et al. Clin Chem 2002; 48: 877–83.
  31. Ridker P.M, Rifai N, Pfeffer M.A et al. Circulation 1999; 100: 230–5.
  32. Bays H.E, Stein E.A, Shah A.K et al. Am J Cardiol 2002; 90: 942–6.
  33. Joukhadar C, Klein N, Prinz M et al. Thromb Haemost 2001; 85: 47–51.
  34. Jialal I, Stein D, Balis D et al. Circulation 2001; 103: 1933–5.
  35. Taylor A.J, Kent S.M, Flaherty P.J et al. Circulation 2002; 106: 2055–60.
  36. van Wissen S, Trip M.D, Smilde T.J et al. Atherosclerosis 2002; 165: 361–6.
  37. Wiklund O, Mattsson-Hult_n L, Hurt-Camejo E, Oscarsson J. J Intern Med 2002; 251: 338–47.
  38. Сусеков А.В. Атмосфера–Кардиология. 2003; 4: 21–4.
  39. Brown G, Albers J.J, Fisher L.D et al. N Engl J Med 1990; 323: 1289–98.
  40. Effects of simvastatin on coronary ateroma: The Multicenter Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633–8.
  41. Waters D, Higginson L, Gladstone P, Kimball B et al. Circulation 1994; 89 (3): 959–68.
  42. Groot E, Jukema J.W, Bruschke A.V et al. Circulation 1995; 91: 2528–400.
  43. Bestehorn H-P, Rensing U.F.E, Roskamm H et al. Eur Heart J 1997; 18 (2): 226–34.
  44. Pitt B, Mancini G.B, Ellis S.G et al. JACC 1995; 26: 1113–
  45. Thompson G.R. Br Heart J 1995; 74: 343–7.
  46. Waters D. Stabilization of coronary aherosclerosis. London: Science Press Ltd, 1994; p. 76.
  47. Thompson G.R, Holyer J, Waters D.D. Curr Opinion Lipidol 1995; 6: 386–8.
  48. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
  49. Strandberg T.E, Pyorala K, Cook T.J et al. Lancet 2004; 364: 771–7.
  50. Sacks F.N, Pfeffer M.A, Moye L.A et al. N Engl J Med 1996; 335: 1001–9.
  51. The long - term prevention with pravastatin in ischemic disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary Heart disease and a broad range of initial cholesterol levels. Ibid 1998; 339: 1349–57.
  52. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high - risk patients: a randomized placebo - controlled trial. Lancet 2002; 360: 7–22.
  53. Cусеков А.В. Тер. арх. 2004; 2: 91–5.
  54. Heart Protection Collaborative Group. Effects of cholesterol - lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high - risk conditions. Lancet 2004; 363: 757–67.
  55. Nissen S.E, Tuzcu E.M, Schoenhagen P et al. JAMA 2004; 291 (9): 1071–80.
  56. Nissen S.E, Tuzcu E.M, Schoenhagen P et al. N Engl J Med 2005; 352 (1): 29–38.
  57. Cannon C.P, Braunwald E, Mc Cabe C.H et al. Ibid 2004; 350: 1495–504.
  58. La Rosa J.C, Grundy S.M, Waters D.D et al. Ibid 2005; 352 (14): 1425–35.
  59. Grundy S.M, Cleeman J.I, Bairey C.N et al. Circulation 2004; 110: 227–39.
  60. Tsyuki R.T, Bungard T.J. Pharmacotherapy 2001; 21 (5): 576–82.
  61. Jones P, Kafonek S, Laurora I et al. Am J Card 1998; 81 (3): 583–7.
  62. Davidson M.H, Stein E.A, Dujovne C.A et al. Ibid 1997; 79: 38–42.
  63. Crouse J.R 3rd, Frohlich J, Ose L et al. Am J Cardiol 1999; 83 (10): 1476–7, A7.
  64. Illingworth D.R, Crouse J.R 3rd, Hunninghake D.B et al. Curr Med Res Opin 2001; 17 (1): 43–50.
  65. Benghozi R, Bortolini M, Jia Y et al. Am J Card 2002; 889: 231–23.
  66. Corsini A, Jacobson T.A, Ballantyne C.M. Drugs 2004; 64 (12): 1305–23.
  67. Сусеков А.В. Сердце. 2004; 3 (3): 1–5.
  68. Сусеков А.В. Сердце. 2005; в печати.
  69. Шальнова С.А., Деев А.Д., Оганов Р.Г. Кардиоваскулярная тер. и профил. 2005; 4 (1): 4–9.
  70. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19): 2486–97.
  71. de Backer G, Ambrosioni E, Borch-Johnsen K et al. Eur Heart J 2003; 24: 1601–10.
  72. Кухарчук В.В., Бубнова М.Г., Кательницкая Л.И. и др. Кардиология. 2003, 5: 42–7.

Copyright (c) 2005 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies